S. Kovats

发表

Identification and Characterization of the Mouse Obesity Gene tubby: A Member of a Novel Gene Family

C. Ebeling, G. Carlson, T. Brody, 1996, Cell.

4-(Pyrazol-4-yl)-pyrimidines as selective inhibitors of cyclin-dependent kinase 4/6.

Rajiv Chopra, Sunkyu Kim, Ming Xu, 2010, Journal of medicinal chemistry.

SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms

G. Dranoff, S. Silver, J. Engelman, 2021, Scientific Reports.

Fragment-Based Discovery of 7-Azabenzimidazoles as Potent, Highly Selective, and Orally Active CDK4/6 Inhibitors.

Paul N. Mortenson, M. Congreve, R. Cheng, 2012, ACS medicinal chemistry letters.

The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models

W. Sellers, G. Caponigro, Alice T. Loo, 2018, Oncotarget.

An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).

Joshua M. Korn, Ping Zhu, Sunkyu Kim, 2013, Cancer discovery.

Identification of underexpressed genes in early- and late-stage primary ovarian tumors by suppression subtraction hybridization.

David I. Smith, J. Chien, J. Lillie, 2002, Cancer research.

Pharmacological and genomic profiling identifies NF-κB–targeted treatment strategies for mantle cell lymphoma

Joshua M. Korn, Tara L. Naylor, Michael P. Morrissey, 2013, Nature Medicine.

In-Depth Characterization and Validation in BRG1-Mutant Lung Cancers Define Novel Catalytic Inhibitors of SWI/SNF Chromatin Remodeling

Joshua M. Korn, W. Sellers, J. Korn, 2019, bioRxiv.

An F 876 L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV 3100 ( Enzalutamide )

Joshua M. Korn, W. Sellers, J. Korn, 2013 .

TULP1 mutation in two extended Dominican kindreds with autosomal recessive Retinitis pigmentosa

J. Ott, S. Jacobson, T. Gilliam, 1998, Nature Genetics.

Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers

P. Hammerman, G. Caponigro, S. Silver, 2019, Molecular Cancer Therapeutics.